Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma
London; NICE; Feb. 8, 2023. 27 p.
Non-conventional
em En
| BIGG
| ID: biblio-1415732
Biblioteca responsável:
BR1.1
ABSTRACT
Evidence-based recommendations on nivolumab (Opdivo) with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma. Commercial arrangement There is a commercial arrangement for nivolumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact UKCommercialEnquiries@bms.com for details.
Texto completo:
1
Coleções:
05-specialized
Base de dados:
BIGG
Assunto principal:
Carcinoma de Células Escamosas do Esôfago
/
Imunoterapia
/
Metástase Neoplásica
Tipo de estudo:
Guideline
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Non-conventional